首页> 美国卫生研究院文献>Internal Medicine >The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group

【2h】

The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group

机译：减少剂量的达沙替尼在慢性期慢性粒细胞白血病患者中的后续治疗功效：关东CML研究组的LD-CML研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective The aim of this study was to prospectively investigate the efficacy and safety profiles of low-dose dasatinib therapy (50 mg once daily).

机译：目的这项研究的目的是前瞻性研究低剂量达沙替尼治疗（每天一次50 mg）的疗效和安全性。

著录项

期刊名称 Internal Medicine
作者
Noriyoshi Iriyama; Kazuteru Ohashi; Satoshi Hashino; Shinya Kimura; Chiaki Nakaseko; Hina Takano; Masayuki Hino; Michihiro Uchiyama; Satoshi Morita; Junichi Sakamoto; Hisashi Sakamaki; Koiti Inokuchi;
展开▼
作者单位

展开▼
年(卷),期 2018(57),1
年度 2018
页码 17–23
总页数 7
原文格式 PDF
正文语种
中图分类基础医学;
关键词
low-dose dasatinib chronic myeloid leukemia LD-CML study;

机译：小剂量达沙替尼;慢性粒细胞白血病;LD-CML研究;

相似文献

外文文献
中文文献
专利

1. The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group [J] . Noriyoshi Iriyama, Kazuteru Ohashi, Satoshi Hashino, Internal medicine. . 2018,第1期

机译：降低剂量的达沙替尼在慢性期慢性粒细胞白血病患者中的后续治疗功效：关东CML研究组的LD-CML研究
2. The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group [J] . Noriyoshi Iriyama, Kazuteru Ohashi, Satoshi Hashino, Internal medicine. . 2018,第1期

机译：降低剂量的达沙替尼在慢性期慢性粒细胞白血病患者中的后续治疗功效：关东CML研究组的LD-CML研究
3. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group [J] . Noriyoshi Iriyama, Shin Fujisawa, Chikashi Yoshida, American Journal of Hematology . 2015,第4期

机译：BCR-ABL1转录物的减半时间缩短是达沙替尼治疗的新诊断的慢性期慢性粒细胞白血病中分子反应实现的新预测因子：关东CML研究组的D-first研究结果
4. Characterization of Leukemia-Associated Antigens in Acute and Chronic Myeloid Leukemias (AML/CML) [C] . J Greiner, M. Ringhoffer, M. Taniguchi, European Haematology Association . 2002

机译：急性和慢性骨髓白血病白血病相关抗原的表征（AML / CML）
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 “ISTAHIT” study [O] . Andreas L. Petzer, Dominik Wolf, Dominic Fong, 1997

机译：大剂量伊马替尼可改善患有费城预处理，BCR-ABL阳性慢性慢性粒细胞白血病的患者的细胞遗传学和分子缓解：随机CELSG III期CML 11“ ISTAHIT”研究的首次结果
7. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study [O] . Jorge E. Cortes, Qian Jiang, Jianxiang Wang, 2020

机译：慢性骨髓白血病患者的慢性骨髓白血病患者的慢性期（CML-CP）患者患者患者尚未达到3个月的伊马替尼治疗：DASCERN随机研究

The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group

摘要

著录项

相似文献

相关主题

期刊订阅